• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Seres Therapeutics Inc. (Amendment)

    11/7/23 12:57:39 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MCRB alert in real time by email
    SC 13G/A 1 form1418.htm

    OMB APPROVAL

    OMB Number: 3235-0145

    Estimated average burden hours per response ….11

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4*)

    SERES THERAPEUTICS, INC.

    (Name of Issuer)

    COMMON STOCK

    (Title of Class of Securities)

    81750R102

    (CUSIP Number)

    October 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    X Rule 13d-1(b)
      Rule 13d-1(c)
      Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     
     

     

    CUSIP No.: 81750R102

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Federated Hermes, Inc.
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: Pennsylvania

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:        5,175,805
    6. Shared Voting Power
    7. Sole Dispositive Power:        5,175,805
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:        5,175,805
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.04%
    12. Type of Reporting Person (See Instructions): HC

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Voting Shares Irrevocable Trust
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: Pennsylvania

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:        5,175,805
    6. Shared Voting Power
    7. Sole Dispositive Power:        5,175,805
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:        5,175,805
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.04%
    12. Type of Reporting Person (See Instructions): OO

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Thomas R. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:        5,175,805
    7. Sole Dispositive Power
    8. Shared Dispositive Power:        5,175,805

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:        5,175,805
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.04%
    12. Type of Reporting Person (See Instructions): IN

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Ann C. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:        5,175,805
    7. Sole Dispositive Power
    8. Shared Dispositive Power:        5,175,805

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:        5,175,805
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.04%
    12. Type of Reporting Person (See Instructions): IN

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      J. Christopher Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:        5,175,805
    7. Sole Dispositive Power
    8. Shared Dispositive Power:        5,175,805

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:        5,175,805
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  4.04%
    12. Type of Reporting Person (See Instructions): IN

     

    Item 1.

    (a) Name of Issuer
      SERES THERAPEUTICS, INC.
    (b) Address of Issuer’s Principal Executive Offices
      200 Sidney Street
      Cambridge, MA  02139

    Item 2.

    (a) Name of Person Filing: Federated Hermes, Inc.
    (b) Address Of Principal Business Office or, if none, Residence
      1001 Liberty Avenue, Pittsburgh, PA  15222-3779
    (c) Citizenship: Pennsylvania
    (d) Title of Class of Securities
      Common Stock
    (e) CUSIP Number: 81750R102
    Item 3.If this statement is filed pursuant to §§240.113d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)   An investment adviser in accordance with §204.13d-1(b)(1)(ii)(E);
    (f)   An employee benefit plan or endowment fund in accordance with §240.13d-19b)(1)(ii)(F);
    (g) X A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)   Group, in accordance with §240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    A. Federated Hermes, Inc.
    (a) Amount beneficially owned:        5,175,805
    (b) Percent of class:  4.04%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:        5,175,805
      (ii) Shared power to vote or to direct the vote:  0
      (iii) Sole power to dispose or to direct the disposition of:        5,175,805
      (iv) Shared power to dispose or to direct the disposition of:  0

     

    B. Voting Shares Irrevocable Trust
    (a) Amount beneficially owned:        5,175,805
    (b) Percent of class:  4.04%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:        5,175,805
      (ii) Shared power to vote or to direct the vote:  0
      (iii) Sole power to dispose or to direct the disposition of:        5,175,805
      (iv) Shared power to dispose or to direct the disposition of:  0

     

     

    C. Thomas R. Donahue
    (a) Amount beneficially owned:        5,175,805
    (b) Percent of class:  4.04%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:        5,175,805
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:        5,175,805

     

    D. Ann C. Donahue
    (a) Amount beneficially owned:        5,175,805
    (b) Percent of class:  4.04%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:        5,175,805
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:        5,175,805

     

     

    E. J. Christopher Donahue
    (a) Amount beneficially owned:        5,175,805
    (b) Percent of class:  4.04%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:        5,175,805
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:        5,175,805

     

    Instruction: Dissolution of a group requires a response to this item.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: X

    Instruction: Dissolution of a group requires a response to this item.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person. NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit “1” Attached
    Item 8.Identification and Classification of Members of the Group: NOT APPLICABLE
    Item 9.Notice of Dissolution of Group: NOT APPLICABLE
    Item 10.Certification
    (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b);
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.
    (b) The following certification shall be included if the statement is filed pursuant to §204.13d-1(c):
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 7, 2023
    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    Date: November 7, 2023
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       
    Date: November 7, 2023
    By: /s/Ann C. Donahue
    Name/Title: Ann C. Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       
    Date: November 7, 2023
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See U.S.C. 1001)

     
     

     

    EXHIBIT “1”

    ITEM 3 CLASSIFICATION OF REPORTING PERSONS

    Identity and Classification of Each Reporting Person

     

    IDENTITY CLASSIFICATION UNDER ITEM 3
    Federated Hermes Equity Funds (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
    Federated Hermes Insurance Series (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
    Federated Equity Management Company of Pennsylvania (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
    Federated Global Investment Management Corp. (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
    Federated Hermes, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    FII Holdings, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Voting Shares Irrevocable Trust (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Thomas R. Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Ann C. Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    J. Christopher Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)

    Federated Hermes, Inc. (the “Parent”) is filing this schedule 13G because it is the parent holding company of Federated Equity Management Company of Pennsylvania and Federated Global Investment Management Corp. (the “Investment Advisers”), which act as investment advisers to registered investment companies and separate accounts that own shares of common stock in SERES THERAPEUTICS, INC. (the “Reported Securities”). The Investment Advisers are wholly owned subsidiaries of FII Holdings, Inc., which is wholly owned subsidiary of Federated Hermes, Inc., the Parent. All of the Parent’s outstanding voting stock is held in the Voting Shares Irrevocable Trust (the “Trust”) for which Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue act as trustees (collectively, the “Trustees”). The Trustees have joined in filing this Schedule 13G because of the collective voting control that they exercise over the Parent. In accordance with Rule 13d-4 under the Securities Act of 1934, as amended, the Parent, the Trust, and each of the Trustees declare that this statement should not be construed as an admission that they are the beneficial owners of the Reported Securities, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial ownership of the Reported Securities.

     
     

    EXHIBIT “2”

    AGREEMENT FOR JOINT FILING OF

    SCHEDULE 13G

    The following parties hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached and any amendments thereto which may be deemed necessary pursuant to Regulation 13D-G under the Securities Exchange Act of 1934:

    1.       Federated Hermes, Inc. as parent holding company of the investment advisers to registered investment companies that beneficially own the securities.

    Voting Shares Irrevocable Trust, as holder of all the voting shares of Federated Hermes, Inc.

    Thomas R. Donahue, individually and as Trustee

    Ann C. Donahue, individually and as Trustee

    J. Christopher Donahue, individually and as Trustee

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other parties unless such party knows or has reason to believe that such information is incomplete or inaccurate.

    It is understood and agreed that the joint filing of Schedule 13G shall not be construed as an admission that the reporting persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.

    Date: November 7, 2023

    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust.
       
    By: /s/Ann C. Donahue
    Name/Title Ann C. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust
       
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue, individually and as Trustee of Voting Shares Irrevocable Trust

    1.       The number of shares indicated represent shares beneficially owned by registered investment companies and separate accounts advised by subsidiaries of Federated Hermes, Inc. that have been delegated the power to direct investment and power to vote the securities by the registered investment companies’ board of trustees or directors and by the separate accounts’ principals. All of the voting securities of Federated Hermes, Inc. are held in the Voting Shares Irrevocable Trust (“Trust”), the trustees of which are Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue (“Trustees”). In accordance with Rule 13d-4 under the 1934 Act, the Trust, Trustees, and parent holding company declare that the filing of this statement should not be construed as an admission that any of the investment advisers, parent holding company, Trust, and Trustees are beneficial owners (for the purposes of Sections 13(d) and/or 13(g) of the Act) of any securities covered by this statement, and such advisers, parent holding company, Trust, and Trustees expressly disclaim that they are the beneficial owners of such securities.

     
     

     

    EXHIBIT “3”

     

     

    EXHIBIT “3”

     

     

     

    Text, letter

Description automatically generated

    Get the next $MCRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MCRB

    DatePrice TargetRatingAnalyst
    5/8/2025$6.00Buy → Neutral
    Chardan Capital Markets
    10/24/2024Neutral → Underweight
    JP Morgan
    6/26/2023$12.00Outperform
    Oppenheimer
    4/21/2023$7.00Neutral
    JP Morgan
    7/23/2021$42.00 → $29.00Buy
    Canaccord Genuity
    7/23/2021$30.00 → $16.00Buy
    Chardan Capital
    7/23/2021$36.00 → $18.00Outperform
    Oppenheimer
    7/23/2021$46.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MCRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

      CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA. Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New resu

      4/29/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

      CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours aft

      4/23/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MCRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Seres Therapeutics Inc.

      SC 13D/A - Seres Therapeutics, Inc. (0001609809) (Subject)

      10/2/24 8:15:49 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Seres Therapeutics Inc. (Amendment)

      SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)

      4/5/24 12:21:59 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Seres Therapeutics Inc. (Amendment)

      SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)

      2/12/24 12:23:38 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MCRB
    SEC Filings

    See more
    • SEC Form S-8 filed by Seres Therapeutics Inc.

      S-8 - Seres Therapeutics, Inc. (0001609809) (Filer)

      5/7/25 4:06:14 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Seres Therapeutics Inc.

      10-Q - Seres Therapeutics, Inc. (0001609809) (Filer)

      5/7/25 10:00:20 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Seres Therapeutics Inc.

      8-K - Seres Therapeutics, Inc. (0001609809) (Filer)

      5/7/25 7:05:18 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MCRB
    Financials

    Live finance-specific insights

    See more
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

      CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours aft

      4/23/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support potential for live biotherapeutics to address inflammatory and immune diseases Company advances SER-155 strategic partnership discussions to acce

      3/13/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MCRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Graves Kurt

      4 - Seres Therapeutics, Inc. (0001609809) (Issuer)

      4/11/25 4:05:12 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kender Richard N

      4 - Seres Therapeutics, Inc. (0001609809) (Issuer)

      4/11/25 4:05:09 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dere Willard H

      4 - Seres Therapeutics, Inc. (0001609809) (Issuer)

      4/11/25 4:05:04 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MCRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seres Therapeutics downgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets downgraded Seres Therapeutics from Buy to Neutral and set a new price target of $6.00

      5/8/25 8:27:44 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics downgraded by JP Morgan

      JP Morgan downgraded Seres Therapeutics from Neutral to Underweight

      10/24/24 6:25:19 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Seres Therapeutics with a new price target

      Oppenheimer resumed coverage of Seres Therapeutics with a rating of Outperform and set a new price target of $12.00

      6/26/23 7:26:19 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MCRB
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

      O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar

      4/8/24 8:00:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

      Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th, following David Arkowitz's retirement. Mr. Arkowitz has served as CFO since June 2021 and will be available to assist in the transition. Ms. Thorell is a seasoned enterprise leader with deep life sciences and biotechnology industry experience in both public and private companies. Prior to joining Seres, she served in executive positions with Evelo Biosciences, Centessa Pharmaceuticals, Palladio Biosciences and Realm Therapeutics. "I am excited to welcome Marella and look forward

      2/26/24 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING

      Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors  CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be

      1/9/24 8:44:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MCRB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

      For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

      4/26/23 6:04:21 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care